Treating type 2 diabetes: How safe are current therapeutic agents?

International Journal of Clinical Practice

Volumn 63, Issue 2, 2009, Pages 321-332

  Philippe, J ^a,b   Raccah, D ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Division of Endocrinology Diabetes and Nutrition Department of Medicine University Hospital ^*  (Switzerland)

^c HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLINIDE; GLUCAGON LIKE PEPTIDE 1 AGONIST; HEMOGLOBIN A1C; METFORMIN; MURAGLITAZAR; PHENFORMIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; TROGLITAZONE; UNCLASSIFIED DRUG; VILDAGLIPTIN; DRUG COMBINATION;

ABDOMINAL PAIN; ACUTE HEMORRHAGIC PANCREATITIS; ADD ON THERAPY; ANEMIA; BONE DENSITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FRACTURE; HEART FAILURE; HEMORRHAGIC PANCREATITIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIVER INJURY; LIVER TOXICITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT PLANNING; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ADVERSE DRUG REACTION; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 58449135068     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01980.x     Document Type: Review

References (105)

1. International Diabetes Federation. Diabetes Atlas. http://www.eatlas.idf. org (accessed 12 October 2008)
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 : 1047 53.
3. Blonde L. State of diabetes care in the United States. Am J Manag Care 2007 13 (Suppl. 2 S36 40.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
5. American Diabetes association. Standards of medical care in diabetes. Diabetes Care 2008 31 : S12 54.
6. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
7. Smith NL, Heckbert SR, Bittner VA et al. Antidiabetic treatment trends in a cohort of elderly people with diabetes. The cardiovascular health study, 1989-1997. Diabetes Care 1999 22 : 736 42.
8. Costa B, Hernández JM. Drug consumption in diabetes mellitus (III). Trends of hypoglycemic agents use and consumption in Tarragona, Catalonia, and Spain (1988-1991). Group for the Study of Diabetes in Tarragona. Med Clin (Barc) 1993 100 : 571 5.
9. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003 26 : 1847 51.
10. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001 63 : 1747 56.
11. Karter AJ, Moffet HH, Liu J et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care 2007 13 : 598 606.
12. Litovitz TL, Klein-Schwartz W, Rodgers GC Jr. et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002 20 : 391 452.
13. Watson WA, Litovitz TL, Rodgers GC Jr. et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005 23 : 589 666.
14. Krentz AJ. Comparative safety of newer oral antidiabetic drugs. Expert Opin Drug Saf 2006 5 : 827 34.
15. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999 131 : 281 303.
16. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000 108 (Suppl. 6a 15S 22S.
17. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 2005 115 : 2047 58.
18. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004 64 : 1339 58.
19. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001 30 : 909 33.
20. Salas M, Caro JJ. Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React Toxicol Rev 2002 21 : 205 17.
21. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003 111 : 405 14.
22. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005 28 : 2948 61.
23. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003 20 : 1016 21.
24. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005 65 : 385 411.
25. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997 26 : 511 22.
26. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994 11 : 223 41.
27. Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004 34 : 535 42.
28. Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003 59 : 91 7.
29. Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 1996 28 : 464 8.
30. Raptis SA, Hatziagelaki E, Dimitriadis G, Draeger KE, Pfeiffer C, Raptis AE. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man. Exp Clin Endocrinol Diabetes 1999 107 : 350 5.
31. Salsburg DS. The UGDP study. JAMA 1971 218 : 1704 5.
32. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006 174 : 169 74.
33. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006 49 : 930 6.
34. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 65.
35. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 43.
36. Kahler KH, Rajan M, Rhoads GG et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 2007 30 : 1689 93.
37. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000 21 : 220 9.
38. Evans JM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab 2008 10 : 350 2.
39. Valensi P, Slama G. Sulphonylureas and vascular risk: facts and controversies. Br J Diabetes Vasc Dis 2006 6 : 159 65.
40. Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006 63 : 929 38.
41. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002 51 : 2074 81.
42. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996 334 : 574 9.
43. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007 30 : 1127 42.
44. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 2007 23 : 905 17.
45. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007 9 : 96 102.
46. Tsilchorozidou T, Batterham RL, Conway GS. Metformin increases fasting plasma PYY in women with PCOS. Clin Endocrinol 2008 69 : 936 42.
47. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008 121 : 149 57.
48. Strack T. Metformin: a review. Drugs Today (Barc) 2008 44 : 303 14.
49. Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther 2001 15 : 137 42.
50. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999 20 : 489 503.
51. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006 1 : CD002967.
52. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999 16 : 179 92.
53. Colca JR, Kletzien RF. What has prevented the expansion of insulin sensitisers? Expert Opin Investig Drugs 2006 15 : 205 10.
54. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002 18 (Suppl. 2 S10 5.
55. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004 27 : 1660 7.
56. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000 132 : 118 21.
57. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2001 135 : 306.
58. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002 136 : 449 52.
59. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000 132 : 121 4.
60. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) TrialInvestigators, Gerstein HC, Yusuf S et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 : 1096 105.
61. Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007 23 : 1493 507.
62. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 31 : 845 51.
63. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007 30 : 1574 6.
64. Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 2007 177 : 723 4.
65. Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes. Expert Opin Drug Saf 2008 7 : 69 78.
66. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 71.
67. DREAM Trial Investigators, Dagenais GR, Gerstein HC et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008 31 : 1007 14.
68. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 89.
69. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes- an interim analysis. N Engl J Med 2007 357 : 28 38.
70. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med 2007 357 : 844 6.
71. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005 294 : 2581 6.
72. Ratner RE, Parikh S, Tou C, GALLANT 9 Study Group. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diab Vasc Dis Res 2007 4 : 214 21.
73. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008 29 : 12 20.
74. Stephan D, Winkler M, Kühner P, Russ U, Quast U. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. Diabetologia 2006 49 : 2039 48.
75. Davies MJ. Insulin secretagogues. Curr Med Res Opin 2002 18 (Suppl. 1 s22 30.
76. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001 358 : 1709 16.
77. Li J, Tian H, Li Q et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007 9 : 558 65.
78. Hu S, Wang S, Dunning BE. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int J Exp Diabetes Res 2001 2 : 63 72.
79. Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004 27 : 1265 70.
80. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005 28 : 2093 9.
81. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999 22 : 960 4.
82. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006 4 : CD005061.
83. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 290 : 486 94.
84. Hanefeld M, Schaper F, Koehler C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drugs Ther 2008 22 : 225 31.
85. Hsiao SH, Liao LH, Cheng PN, Wu TJ. Hepatotoxicity associated with acarbose therapy. Ann Pharmacother 2006 40 : 151 4.
86. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005 1 : 22 31.
87. Glass LC, Qu Y, Lenox S et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin 2008 24 : 639 44.
88. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008 14 : 285 92.
89. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005 143 : 559 69.
90. Barnett A. Exenatide. Expert Opin Pharmacother 2007 8 : 2593 608.
91. US Food and Drug Administration. http://www.fda.gov/CDER/drug/InfoSheets/ HCP/exenatide2008HCP.htm (accessed 12 October 2008)
92. Nathan DM. Finding new treatments for diabetes - how many, how fast. how good? N Engl J Med 2007 356 : 437 40.
93. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003 40 : 209 94.
94. Wysham C, Lush C, Zhang B, Maier H, Wilhelm K. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin 2008 24 : 79 85.
95. Hollander P, Maggs DG, Ruggles JA et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004 12 : 661 8.
96. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005 28 : 601 31.
97. Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes Obes Metab 2008 10 (Suppl. 1 1 7.
98. Garber A, Marre M, Blonde L et al. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes. Diabetes Obes Metab 2003 5 : 171 9.
99. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 2002 4 : 368 75.
100. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008 23 : 611 4.
101. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006 8 : 156 63.
102. Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 48 : 1093 104.
103. Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007 46 : 1 12.
104. Agency for Healthcare Research and Quality. http://effectivehealthcare. ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=6&DociID=40 2007 (accessed 12 October 2008)
105. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007 147 : 386 99.